“Prevention is crucial in the fight against HIV and AIDS, and a vaccine is one of the most powerful prevention tools we know to combat infectious diseases,” said Professor Brian Gazzard, Research Director at the St. Stephen’s AIDS Trust and the principle investigator of this trial. “We hope this trial will contribute to a better understanding of how to induce with a vaccine an immune response to protect against HIV infection and AIDS.”
The news follows promising results recently announced by IAVI and partners for one of the two vaccine candidates to be tested, the MVA-based TBC-M4, which in a recent phase I trial generated modest immune responses in all volunteers who received the highest dose. According to Patricia Fast, Chief Medical Officer at the International AIDS Vaccine Initiative, “The responses observed with this vaccine candidate warrant further research to improve immune activation. We have learned from other studies that a prime-boost regimen has the potential to achieve just this.”
That is why the new trial will include a DNA-based vaccine candidate called ADVAX to prime the immune system. Previous Phase I studies with different DNA and MVA-based HIV vaccines in combination have shown that this prime-boost regimen was safe and well tolerated, and also able to generate enhanced immune responses when compared with the responses generated by either vaccine alone. The ADVAX vaccine candidate also offers economic value; it is relatively easy and cheap to manufacture, which makes it particularly appealing for use in the developing world.
A separate Phase I trial testing ADVAX and the MVA-based candidates in a prime-boost regime is planned for India. This trial would use a different mode of administration for the priming vaccine, different dosages and different vaccine regimens. Collectively, the results of both trials will help determine whether further development of both AIDS vaccine candidates in a prime-boost combination is warranted.
Deborah Jack, Chief Executive of the National AIDS Trust, comments: “The UK has always been a leader in the quest for new technologies to prevent HIV. Hosting a vaccine trial in London is a great opportunity to continue doing our part in the global fight against HIV and AIDS. Like any medical development, discovering an HIV vaccine is a naturally long process but when a vaccine is found it could save millions of lives globally, not just in the developing world but also in the UK.”About the vaccine candidates
The vaccine candidate ADVAX is a plasmid DNA vaccine containing HIV-1 subtype C genes env, gag, pol, nef and tat. The vaccine was designed by the Aaron Diamond Research Centre in New York, through collaboration with Rockefeller University in New York and the International AIDS Vaccine Initiative.
It should be noted that since both vaccine candidates contain only synthetic copies of part of HIV’s genetic material, they cannot cause HIV infection.
ADVAX will be administered with a needle-free device (Biojector 2000), and the trial will also assess whether this delivery mechanism provides benefits over regular injection with a needle and syringe. ”Needle-free injection of a DNA vaccine can provide enhanced immune responses compared with administration by needle and syringe,” according to Dr. Richard Stout, Executive Vice President and Chief Medical Officer of Bioject Medical Technologies Inc., manufacturer of the device.About the trial
In addition to using standard immunology assays to measure the responses following vaccination, the trial will also evaluate a novel viral suppression assay. This assay provides a functional assessment of the immune response by measuring anti-viral activity. “There are indications from previous clinical studies that the laboratory assays currently used in HIV vaccine clinical trials are not an accurate predictor of whether a vaccine can prevent or control HIV infection,” said Dr. Jill Gilmour, Senior Director of Clinical Research at IAVI. “We urgently need to identify which laboratory tests give us insight into whether a person will resist infection with HIV or development of AIDS. This will enable researchers to select the most promising vaccine candidates for large-scale efficacy testing.”
It is expected that the trial will take 14 months to complete. The trial is fully sponsored by the International AIDS Vaccine Initiative.
Hester Kuipers | alfa
Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center
Study advances gene therapy for glaucoma
17.01.2018 | University of Wisconsin-Madison
What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...
For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.
Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...
At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.
No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...
Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.
Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...
The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...
08.01.2018 | Event News
11.12.2017 | Event News
08.12.2017 | Event News
18.01.2018 | Earth Sciences
18.01.2018 | Business and Finance
18.01.2018 | Medical Engineering